5.62

5.86% -0.35

After Hours: 5.56 -0.06 -1.07%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $5.62, with a volume of 50,896. It is down -5.86% in the last 24 hours and up +0.36% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$5.97

Open:

$5.81

24h Volume:

50,896

Relative Volume:

0.44

Market Cap:

$46.28M

Revenue:

$140.46M

Net Income/Loss:

$-146.34M

P/E Ratio:

-4.4252

EPS:

-1.27

Net Cash Flow:

$-117.73M

1W Performance:

+13.54%

1M Performance:

+0.36%

6M Performance:

-54.70%

1Y Performance:

-64.65%

1-Day Range:

$5.52

$5.86

1-Week Range:

$4.89

$6.56

52-Week Range:

$3.51

$18.00

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1154)

Industry

Biotechnology (677)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

279

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	5.62	46.28M	140.46M	-146.34M	-117.73M	-1.27
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 12, 2025

Medidata Solutions, Inc. Announces Expanded Partnership with Karyopharm Therapeutics - marketscreener.com

Apr 12, 2025

Apr 07, 2025

Karyopharm therapeutics CEO Richard Paulson sells $916 in stock By Investing.com - Investing.com South Africa

Apr 07, 2025

Karyopharm therapeutics CEO Richard Paulson sells $916 in stock - Investing.com

Apr 07, 2025

Apr 02, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025

Apr 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Apr 01, 2025

Mar 26, 2025

KPTI stock touches 52-week low at $5.55 amid market challenges - Investing.com

Mar 26, 2025

Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com

Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 11, 2025

Mar 07, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada

Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Karyopharm Therapeutics Executives Sell Shares - TradingView

Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com

Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India

Mar 06, 2025

Mar 04, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World

Mar 04, 2025

Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire

Mar 03, 2025